Multiple Sclerosis
An immune-mediated disease of the central nervous system — not an explanation for tingling, fatigue or a spot on a scan
What it is
Multiple sclerosis is an immune-mediated disease of the brain, spinal cord and optic nerves. The immune system attacks myelin — the insulating sheath around nerve fibres — which slows or blocks the signals travelling along them, and that is what produces symptoms: an eye that goes painful and blurred (optic neuritis), numbness climbing a limb, weakness, imbalance, double vision. Two things about that description matter. Demyelination is not the whole story: there is also damage to the nerve fibres themselves, and that neuroaxonal injury is what drives the slow accumulation of disability over decades, which is why 'MS is about inflammation' is only half true. And MS is not one course. A clinically isolated syndrome is a first episode that may or may not become MS. Relapsing-remitting MS — the commonest presentation — means attacks with recovery in between. Secondary progressive MS is what some relapsing disease evolves into. Primary progressive MS accumulates disability from the start without distinct relapses, and behaves differently enough that most treatments developed for relapsing disease do not work in it. The course varies enormously between people, and a diagnosis is not a prognosis.
Why it matters
MS occupies a strange position: it is simultaneously over-suspected and under-recognised. It is over-suspected because its early symptoms — fatigue, tingling, trouble concentrating — are among the most common experiences in medicine, and because brain MRI scans routinely show white-matter spots that are usually nothing. When those two facts meet, misdiagnosis follows, and it is not rare or harmless. In a multicentre study of 110 people misdiagnosed with MS, the conditions they actually had were led by migraine (22%), fibromyalgia (15%), and non-specific neurological symptoms with an abnormal MRI (12%); a third had carried the wrong diagnosis for a decade or more, and 70% had been given disease-modifying therapy — drugs with real risks — for a disease they did not have. It is under-recognised in the opposite direction, where genuine episodes get attributed to stress and the diagnosis arrives late. The purpose of this page is to hold the line in both directions: to explain why a white-matter spot is not MS, and why a genuine neurological episode deserves a neurologist rather than reassurance.
What BioSignal knows about treating this
What works for Multiple Sclerosis
BioSignal’s clinical summary, most important first.
- Disease-modifying therapy — reduces relapses and new inflammatory lesion activity; it modifies the disease, it does not cure it
- High-dose corticosteroids for acute relapses — speeds recovery from an attack; does not change the long-term outcome
- Rehabilitation and physiotherapy — central to function, and under-prescribed relative to drugs
- Exercise — safe and beneficial, contrary to the older advice to rest
- Symptom-directed treatment — for spasticity, bladder dysfunction, pain, fatigue and mood
- Smoking cessation — associated with slower progression, and one of the few things fully within reach
- Autologous haematopoietic stem-cell transplantation — evidence in highly active relapsing disease in selected patients at experienced centres; not a general option and not what stem-cell clinics abroad are selling
Signal Records relevant to this condition
Interventions and contributing factors — some of these records describe a cause rather than a cure. The rating shown is BioSignal’s confidence in that Signal Record, not a claim about how well it treats this condition. Open any of them for the full evidence.
- Vitamin DHigh confidence
Effective for deficiency and for bone health in at-risk groups. For broad disease prevention in adults who are already replete, the largest trials are null — and confidence in that null is high. Routine testing of healthy adults is not supported.
- Smoking CessationHigh confidence
One of the highest-value interventions in medicine — roughly a decade of life, and about 90% of the excess risk avoided if you stop before 40. The treatments are well evidenced and unequal: varenicline, nicotine e-cigarettes and cytisine roughly double quit rates, combination NRT is close behind, and a single patch or willpower alone is considerably weaker. Nicotine replacement is not as dangerous as smoking, and believing otherwise keeps people smoking.
New to this? Read these first
How this usually unfolds
- Recognize risk factors
- Get diagnosed
- Track key biomarkers
- Lifestyle first
- Evidence-based treatment
- Long-term monitoring
Who is at risk
- Epstein-Barr virus infection — the strongest known factor, and now considered the leading candidate cause
- Female sex — MS is substantially more common in women
- Age 20-40 at onset, typically
- Genetic susceptibility and family history — MS is not inherited in a simple pattern, but risk is higher in relatives
- Higher latitude and low vitamin D status — a consistent association whose causal role remains unsettled
- Smoking — associated with higher risk and with faster progression
- Adolescent obesity
How it's diagnosed
MS is diagnosed by a neurologist using clinical criteria, and the logic is the part worth understanding because it is what stops a scan from becoming a diagnosis. The requirement is evidence of damage scattered in SPACE (more than one area of the central nervous system) and in TIME (more than one episode, or evidence of both older and newer damage) — and, crucially, that no better explanation exists. That last clause does most of the work and is the one people skip. The current framework is the McDonald criteria, revised in 2024, which incorporate MRI, cerebrospinal fluid findings and other paraclinical evidence, and which are explicitly designed to be applied by clinicians to people with a typical clinical presentation — not run as a checklist against a scan report by someone at home. MRI is central but is not a test for MS: white-matter lesions are common with age, migraine, high blood pressure and smoking, and their appearance, location and evolution are what a neuroradiologist interprets, not their mere presence. Oligoclonal bands in the cerebrospinal fluid support the diagnosis and now carry more weight in the criteria, but they occur in other inflammatory conditions too. Evoked potentials can demonstrate slowed conduction that examination misses. No single result on this list makes or excludes the diagnosis.
Key biomarkers
Lifestyle
Explore this condition across BioSignal
Related Foundations
Related Signal Records
Frequently asked questions
My MRI showed white-matter spots. Do I have MS?
Almost certainly not, on that basis alone. White-matter spots are one of the commonest incidental findings in medicine. They accumulate with age, and they are associated with migraine, high blood pressure, smoking, diabetes and small-vessel disease — none of which is MS. What matters to a neuroradiologist is not whether spots exist but what they look like, where they sit, whether they have the shape and distribution typical of demyelination, and whether they change over time. That is why MS is not diagnosed from a scan. The formal requirement is damage disseminated in space and in time, in someone with a compatible clinical picture, AND — the clause that does the most work and gets skipped — with no better explanation. The consequence of ignoring that is documented rather than hypothetical: in a study of people misdiagnosed with MS, 12% turned out to have non-specific neurological symptoms plus an abnormal MRI, and nothing more. If you have been handed a report mentioning white-matter changes and no symptoms that a neurologist finds concerning, the overwhelmingly likely answer is that this is not MS. If you do have unexplained neurological symptoms, the scan is one input to an assessment — not the assessment.
Could my fatigue, tingling or brain fog be MS?
They could be, and usually they are not — and this page is going to be careful in both directions rather than pick a comfortable one. Fatigue, intermittent tingling and trouble concentrating are extraordinarily common, and the overwhelming majority of people who have them do not have MS; they are also, taken alone, exactly the symptoms MS does NOT typically announce itself with. MS more characteristically presents with a discrete neurological episode that lasts days to weeks and then partly or fully recovers: an eye that becomes painful and loses vision or colour (optic neuritis), numbness that spreads over hours and persists, double vision, weakness or a loss of balance. Symptoms that are objective, that localise to a place in the nervous system, and that persist rather than flicker are what raise suspicion. The misdiagnosis data make the point from the other side: the conditions most often mistaken for MS were migraine and fibromyalgia, not because those are trivial but because non-specific symptoms plus a scan is a trap. If you have a persistent, objective neurological symptom, ask for a neurological assessment. If you have fatigue and tingling and a normal examination, MS is an unlikely explanation, and the useful next step is finding the real one — which BioSignal cannot do from a page either.
Does disease-modifying therapy cure MS?
No — and the distinction is the whole point of the name. Disease-modifying therapies reduce relapses and reduce new inflammatory activity on MRI, and the ones with strong evidence do that substantially. What they do not do is repair damage already done or stop the disease. They are also not one thing: they differ enormously in how effective they are, how they are taken, what they require in monitoring, and what they risk — from relatively benign side-effect profiles to serious infection risk and rare but severe complications. Higher efficacy generally comes with higher risk, which is the trade-off that makes drug selection a genuine specialist decision rather than a ranking, and it is why BioSignal is not going to name a best one. Two honest points. Progressive disease has historically been the hard problem: most treatments developed for relapsing MS do not work in primary progressive MS, and ocrelizumab's trial in that population was notable precisely because it was the first to show benefit. And long-term data are still accumulating — the question of how much these drugs change disability decades out, rather than relapse counts over two years, is genuinely less settled than the marketing implies.
What is a relapse, and is this one?
A relapse is new or worsening neurological symptoms lasting more than 24 hours, in the absence of infection or fever, and not explained by something else — typically developing over days and then improving over weeks. What it is NOT is a bad day. The distinction people most need is the pseudo-relapse: old symptoms temporarily reappearing or worsening because of heat, infection, stress, or exhaustion. If you have had a urinary infection, or you have been overheated, or you have a fever, symptoms that were previously damaged pathways can resurface — the conduction in already-injured nerves is temperature and metabolically sensitive. That is frightening and feels identical to a relapse, but it reflects a temporary failure in old damage rather than new inflammation, and it settles when the trigger is treated. This matters because pseudo-relapses do not need steroids, and the treatment for one is usually finding the infection. The practical version: new symptoms with a fever or an infection are a reason to be checked for the infection first. Genuinely new neurological symptoms lasting more than a day, without a trigger, are a reason to contact your MS team.
Do steroids help a relapse?
They help it end faster, and that is all they do — which is worth knowing before you decide whether you want them. High-dose corticosteroids speed recovery from an acute relapse. They do not change how well you recover in the end, they do not alter the long-term course of the disease, and they are not a treatment for MS itself. Because the benefit is speed rather than outcome, the decision is a real one and depends on how disabling the relapse is: a relapse that is interfering with walking or vision is a different proposition from mild sensory symptoms that are already improving. Steroids also carry costs — sleep disruption, mood changes, blood-sugar effects, and with repeated courses, bone and other consequences. Many mild relapses are reasonably managed without them. The framing that helps: steroids are for getting through the attack, disease-modifying therapy is for having fewer attacks, and rehabilitation is for function. They are three different jobs and one does not substitute for another.
What about stem cells, special diets, or the vein procedure?
These need separating, because one has real evidence in a narrow group and the others do not. Autologous haematopoietic stem-cell transplantation (AHSCT) is genuine: in a randomised trial, it outperformed continued disease-modifying therapy in people with highly active relapsing MS who were still relapsing despite treatment. But read the population — that is a specific, selected group with active inflammatory disease, treated at experienced centres, in a procedure that carries real risks including death. It is not a general MS treatment, and it bears very little resemblance to what overseas 'stem-cell clinics' sell to people with progressive disease, which is not the same intervention and is not supported. CCSVI — the theory that MS is caused by blocked neck veins, treated by 'liberation' venoplasty — has been tested and does not survive. A systematic review concluded that CCSVI is a poorly reproducible and clinically irrelevant construct, that most independent investigators could not reproduce the original findings, that the procedure has no proven efficacy, that it may worsen disease activity, and that it has caused serious harm including stroke, jugular thrombosis, stent migration and hydrocephalus — its authors concluded it should stop being offered. On diets: no diet has been shown to cure or stop MS. Eating well, exercising, and not smoking are worth doing and are not a treatment. The pattern to notice is that the interventions sold hardest to people with progressive MS are the ones with the least evidence, and that is not a coincidence.
What causes MS — is it Epstein-Barr virus?
EBV is now the leading candidate, and the evidence behind that shift is unusually strong for an association claim. In a cohort of more than 10 million young adults in the US military, of whom 955 developed MS, the risk of MS increased 32-fold after EBV infection — and was not increased after infection with other viruses, including cytomegalovirus, which spreads similarly. Neurofilament light chain, a marker of nerve-fibre damage, rose only after EBV seroconversion. The authors concluded that these findings cannot be explained by any known risk factor and suggest EBV as the leading cause of MS. Two caveats keep this honest and matter to you. This is still observational evidence, however compelling the design — a 32-fold association with a temporal sequence and a specificity against a control virus is about as strong as observational epidemiology gets, but it is not a trial. And EBV infects the overwhelming majority of adults while MS remains uncommon, so EBV is clearly not sufficient on its own: something else — genetic susceptibility, other exposures — determines who goes on to develop MS. What this does not mean is that you can catch MS, or that anything you did caused it.
When should MS symptoms be treated as urgent?
When the nervous system is doing something new and serious, or when treatment has made you vulnerable. Sudden symptoms that could be a stroke — face droop, one-sided weakness, slurred speech, sudden severe symptoms coming on over minutes rather than days — are an emergency and should be treated as a stroke until proven otherwise, not assumed to be a relapse; the onset speed is the clue, because MS relapses build over days. Seek urgent care for new loss of vision, severe new weakness, an inability to walk, or a sudden inability to pass urine, which can indicate cord involvement and needs same-day assessment. If you are on immunosuppressive disease-modifying therapy, a fever or a serious infection is more urgent for you than for other people, and 'I'm on an immune drug' is information to lead with rather than mention in passing. Rapid deterioration over hours to days deserves contact with your MS team. Most MS symptoms are not emergencies, and the everyday experience of the condition is not the list above — but these specific presentations are the exceptions, and the stroke one in particular is a mistake that runs in the dangerous direction.
Evidence summary
Multiple sclerosis is an immune-mediated disease of the central nervous system involving both demyelination and neuroaxonal injury, the latter driving long-term disability accumulation. It is a heterogeneous condition — clinically isolated syndrome, relapsing-remitting, secondary progressive and primary progressive courses differ in behaviour and in treatment response — and the course varies substantially between individuals, so diagnosis is not prognosis. Diagnosis follows the McDonald criteria, revised in 2024, requiring dissemination in space and time in a compatible clinical presentation with no better explanation; it is a clinician's framework applied to a person, not a checklist applied to a scan. MRI is central but not diagnostic in isolation: white-matter lesions are common with age, migraine, hypertension and smoking, and appearance, location and evolution matter rather than presence. Oligoclonal bands support the diagnosis and are weighted more heavily in the 2024 criteria but are not specific. Misdiagnosis is common and consequential: among 110 misdiagnosed patients, the actual diagnoses were led by migraine (22%), fibromyalgia (15%) and non-specific neurological symptoms with an abnormal MRI (12%); a third carried the misdiagnosis for a decade or more, 72% had an earlier opportunity for correct diagnosis, and 70% received disease-modifying therapy for a disease they did not have. Epstein-Barr virus is the leading candidate cause: in a cohort of over 10 million US military personnel with 955 incident MS cases, EBV infection was associated with a 32-fold increase in MS risk with no comparable increase after cytomegalovirus, and neurofilament light rose only after EBV seroconversion — powerful observational evidence, though EBV infects most adults while MS remains uncommon, so it is clearly not sufficient alone. Disease-modifying therapy reduces relapses and inflammatory MRI activity but is not curative and does not repair existing damage; agents differ widely in efficacy, monitoring burden and risk, so selection is a specialist decision and is not adjudicated here. Progressive disease remains the harder problem, with ocrelizumab's primary progressive trial notable as the first to demonstrate benefit in that population. Corticosteroids speed recovery from relapses without altering long-term outcome. Pseudo-relapses — old symptoms resurfacing with heat, infection or fever — are not new inflammation and do not require steroids. Autologous haematopoietic stem-cell transplantation outperformed continued disease-modifying therapy in a randomised trial in highly active relapsing MS, in a selected population at experienced centres, and is not equivalent to commercial stem-cell tourism. CCSVI and 'liberation' venoplasty have been tested and rejected: a systematic review concluded CCSVI is a poorly reproducible and clinically irrelevant construct, that the procedure has no proven efficacy, may exacerbate disease activity, and has caused serious adverse events including stroke, jugular thrombosis, stent migration and hydrocephalus, and that it should stop being offered. No diet has been shown to cure or halt MS. This page covers MS; migraine, stroke, peripheral neuropathy, fibromyalgia, B12 deficiency, fatigue and anxiety are separate, and an incidental abnormal MRI is not a diagnosis.
References & sources
- Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol 2025;24(10):850-865 (PMID 40975101; DOI 10.1016/S1474-4422(25)00270-4)
- Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17(2):162-173 (PMID 29275977; DOI 10.1016/S1474-4422(17)30470-2)
- Solomon AJ, Bourdette DN, Cross AH, et al. The contemporary spectrum of multiple sclerosis misdiagnosis: a multicenter study. Neurology 2016;87(13):1393-1399 (PMID 27581217; DOI 10.1212/WNL.0000000000003152)
- Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 2022;375(6578):296-301 (PMID 35025605; DOI 10.1126/science.abj8222)
- Montalban X, Hauser SL, Kappos L, et al. (ORATORIO Clinical Investigators). Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376(3):209-220 (PMID 28002688; DOI 10.1056/NEJMoa1606468)
- Burt RK, Balabanov R, Burman J, et al. (MIST Trial). Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA 2019;321(2):165-174 (PMID 30644983; DOI 10.1001/jama.2018.18743)
- Tsivgoulis G, Faissner S, Voumvourakis K, et al. 'Liberation treatment' for chronic cerebrospinal venous insufficiency in multiple sclerosis: the truth will set you free. Brain Behav 2015;5(1):3-12 (PMID 25722945; DOI 10.1002/brb3.297)
Educational information — not medical advice
Is this condition page clear, accurate, and useful? Your feedback shapes what we review next.
Give feedback